Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has provided an update.
CARsgen Therapeutics Holdings Limited announced updated long-term follow-up results for its product, zevorcabtagene autoleucel, at the 22nd International Myeloma Society Annual Meeting. This CAR T-cell product, targeting BCMA for the treatment of relapsed/refractory multiple myeloma, highlights the company’s ongoing efforts to innovate in the field of cancer treatment, potentially strengthening its position in the biopharmaceutical industry.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in areas such as hematologic malignancies, solid tumors, and autoimmune diseases. The company has developed comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen’s mission is to become a global leader in biopharmaceuticals by providing innovative and differentiated cell therapies worldwide.
Average Trading Volume: 2,716,032
Technical Sentiment Signal: Hold
Current Market Cap: HK$12.41B
Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.